COVID, FDA and vaccines
Digest more
The agency says it’s open to offering speedy approval pathways for new pain medications that can fight the ongoing opioid addiction crisis.
The US FDA has issued new guidance on ways to expand development of non-opioid treatment options for chronic pain.
Journavx (suzetrigine) 50 mg oral tablets, the first-in-class non-opioid analgesic for moderate to severe acute pain, was approved by the FDA in January 2025, marking a regulatory milestone that the agency said expanded non-opioid treatment options for acute pain.
The FDA has issued new draft guidance to promote safe and effective non-opioid treatments, and to curb prescription-related opioid misuse. In a press release, the FDA said that the cornerstone of the guidelines,
With a flurry of recent Big Pharma investment in radiopharmaceutical therapeutics, the FDA issued draft guidance last month in a move former FDA Commissioner Stephen Hahn sees as the regulator “trying to get ahead on a new set of therapy that they see becoming very important for cancer.
New FDA rules limit COVID-19 vaccines to older adults, high-risk patients, or those with prescriptions, leaving SC pharmacies and doctors concerned about access.
Unlike past years, the new COVID vaccines are no longer available to everyone 6 months and older, according to the Pfizer news release. Instead, the FDA is restricting access to COVID shots to people at higher risk for severe illness.
The U.S. Food and Drug Administration released draft guidance to advance safe and effective nonopioid treatment options and reduce risks tied to prescription opioid misuse.
SAN FRANCISCO (KGO) -- As schools get back into session, families will be dealing with the inevitable notifications of potential exposures to COVID and knowing when to test. New suggested guidelines from the FDA are different than what local health ...